Skip to content

Insider · CIK 0001591178

Richard Klausner

director

Files at LYEL (Lyell Immunopharma, Inc.). First filing Mar 18, 2025, latest Mar 18, 2025.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
1 / 0
$95k bought, $0 sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

LYEL: Lyell Immunopharma, Inc.

LYELOct 9, 2026 · close 8.71

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
31Weak
LYELbuy
Lyell Immunopharma, Inc.
$95k
158,000 shares
+23%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
May 15, 2025LYEL
Lyell Immunopharma, Inc.
AGrant or award
Option (right to buy)derivative
+130,000$0.00$0130,000May 19, 2025
Mar 14, 2025LYEL
Lyell Immunopharma, Inc.
POpen-market purchase
Common Stockindirect: Grantor and Trustee
+158,000$0.60$95k843,365Mar 18, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Richard Klausner: insider trades and track record | InsiderTell